PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1635102
PUBLISHER: Prescient & Strategic Intelligence | PRODUCT CODE: 1635102
Benign Prostatic Hyperplasia Treatment Market Size & Share Analysis - Trends, Drivers, Competitive Landscape, and Forecasts (2025 - 2030)
The global benign prostatic hyperplasia (BPH) treatment market is projected to grow from $13.7 billion in 2024 to $19.1 billion by 2030, reflecting a compound annual growth rate (CAGR) of 5.7% during the forecast period.
This growth is primarily driven by the increasing prevalence of BPH, a condition commonly associated with aging in men, leading to urinary difficulties. The rising geriatric male population significantly contributes to the demand for effective BPH treatments. Additionally, there is a growing preference for minimally invasive surgeries due to their benefits, such as reduced post-operative pain, shorter hospital stays, and quicker recovery times. Technological advancements have led to the development of novel treatment options, including mechanical implants like UroLift, which improve urine flow with minimal disruption, and prostatic artery embolization, a technique that reduces prostate size by blocking its blood supply.
Key Insights
Drug treatments, including alpha-blockers and 5-alpha-reductase inhibitors, remain the first line of therapy for BPH, accounting for a significant share of the treatment market. Their non-invasive nature and effectiveness in symptom management contribute to their widespread use.
There is an increasing adoption of minimally invasive surgical options, such as transurethral resection of the prostate (TURP) and laser-based treatments, due to their efficacy and reduced recovery times. These procedures are becoming more prevalent as patients seek alternatives to traditional open surgeries.
The home healthcare segment is expected to witness substantial growth, driven by the increasing availability of home-based treatments and patient preference for receiving care in a comfortable environment. This trend is supported by advancements in telemedicine and remote monitoring technologies.
North America holds the largest share of the BPH treatment market, attributed to a high prevalence of the condition, advanced healthcare infrastructure, and early adoption of innovative treatment modalities. The presence of key market players in the region further supports market dominance.
The Asia-Pacific region is anticipated to experience the fastest growth during the forecast period, driven by an increasing geriatric population, rising healthcare awareness, and improving access to medical facilities. Economic development and healthcare reforms in countries like China and India contribute to this expansion.
Continuous research and development efforts are leading to the introduction of advanced treatment options, such as prostatic artery embolization and novel mechanical implants, offering patients less invasive and more effective solutions. These innovations are expected to enhance patient outcomes and expand treatment choices.
Rising healthcare spending globally facilitates the adoption of advanced BPH treatments, as patients and healthcare providers invest in effective management options to improve quality of life. Government initiatives and insurance coverage expansions also play a role in this trend.
The BPH treatment market is characterized by fragmentation, with numerous pharmaceutical companies and medical device manufacturers offering a variety of treatment options. This competitive landscape drives innovation and provides patients with multiple therapeutic choices.
Table of Contents
Chapter 1. Research Background
- 1.1 Research Objectives
- 1.2 Market Definition
- 1.3 Analysis Period
- 1.4 Market Data Reporting Unit
- 1.4.1 Value
- 1.5 Market Size Breakdown by Segment
- 1.5.1 Market Segmentation by Type
- 1.5.2 Market Segmentation by End User
- 1.5.3 Market Segmentation by Region
- 1.6 Key Stakeholders
Chapter 2. Research Methodology
- 2.1 Secondary Research
- 2.1.1 Paid
- 2.1.2 Unpaid
- 2.1.3 P&S Intelligence Database
- 2.2 Primary Research
- 2.2.1 Breakdown of Primary Research, by Designation
- 2.2.2 Breakdown of Primary Research, by Company Type
- 2.3 Market Size Estimation
- 2.4 Data Triangulation
- 2.5 Currency Conversion Rates
- 2.6 Notes and Caveats
Chapter 3. Executive Summary
- 3.1 U.S.
- 3.2 Canada
- 3.3 Germany
- 3.4 France
- 3.5 U.K.
- 3.6 China
- 3.7 Japan
- 3.8 South Korea
- 3.9 India
Chapter 4. Voice of Industry Experts/KOLs
Chapter 5. Definition of Market Segments
- 5.1 By Type
- 5.1.1 Drug Treatment
- 5.1.1.1 Alpha blockers
- 5.1.1.1.1 Alfuzosin
- 5.1.1.1.2 Doxazosin
- 5.1.1.1.3 Tamsulosin
- 5.1.1.1.4 Silodosin
- 5.1.1.1.5 Other alpha blockers
- 5.1.1.2 Alpha reductase inhibitors
- 5.1.1.2.1 Finasteride
- 5.1.1.2.2 Dutasteride
- 5.1.1.3 Others
- 5.1.1.1 Alpha blockers
- 5.1.2 Surgical Treatment
- 5.1.2.1 TURP
- 5.1.2.2 TUMT
- 5.1.2.3 TUNA
- 5.1.2.4 Laser therapy
- 5.1.2.5 Prostatic stenting
- 5.1.2.6 UroLift therapy
- 5.1.2.7 Rezum therapy
- 5.1.2.8 Others
- 5.1.1 Drug Treatment
- 5.2 By End User
- 5.2.1 Home Healthcare
- 5.2.2 Hospitals & Clinics
Chapter 6. Industry Outlook
- 6.1 Market Dynamics
- 6.1.1 Trends
- 6.1.1.1 Technological advancements
- 6.1.1.2 Product approvals and launches
- 6.1.2 Drivers
- 6.1.2.1 Increasing geriatric male population
- 6.1.2.2 Rising prevalence of BPH
- 6.1.2.3 Surging awareness of BPH disorders
- 6.1.3 Impact Analysis of Drivers on Market Forecast
- 6.1.4 Restraints
- 6.1.4.1 Side effects associated with BPH medication
- 6.1.4.2 Unfavorable healthcare reforms
- 6.1.5 Impact Analysis of Restraints on Market Forecast
- 6.1.1 Trends
- 6.2 Impact of COVID 19
- 6.3 Porter's Five Forces Analysis
- 6.3.1 Bargaining Power of Buyers
- 6.3.2 Bargaining Power of Suppliers
- 6.3.3 Intensity of Rivalry
- 6.3.4 Threat of New Entrants
- 6.3.5 Threat of Substitutes
Chapter 7. Policy and Regulatory Landscape
- 7.1 Regulations for BPH Treatment Devices
- 7.1.1 North America
- 7.1.2 Europe
- 7.1.3 APAC
- 7.1.4 LATAM
- 7.1.5 MEA
- 7.2 Regulatory Framework for Drug Approval
- 7.2.1 U.S.
- 7.2.2 Europe
- 7.2.2.1 Centralized procedure
- 7.2.2.2 Mutual recognition procedure
- 7.2.2.3 Decentralized procedure
- 7.2.2.4 Nationalized procedure
- 7.2.3 Japan
Chapter 8. Global Market Size and Forecast
- 8.1 Overview
- 8.2 Market Revenue, by Type
- 8.2.1 Global Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 8.2.1.1 Global benign prostatic hyperplasia alpha blockers market revenue, by type
- 8.2.1.2 Global benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
- 8.2.2 Global Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
- 8.2.1 Global Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 8.3 Market Revenue, by End User
- 8.4 Market Revenue, by Region
Chapter 9. North America Market Size and Forecast
- 9.1 Overview
- 9.2 Market Revenue, by Type
- 9.2.1 North America Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 9.2.1.1 North America benign prostatic hyperplasia alpha blockers market revenue, by type
- 9.2.1.2 North America benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
- 9.2.2 North America Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
- 9.2.1 North America Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 9.3 Market Revenue, by End User
- 9.4 Market Revenue, by Country
Chapter 10. U.S. Market Size and Forecast
- 10.1 Market Revenue, by Type
- 10.1.1 U.S. Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 10.1.1.1 U.S. benign prostatic hyperplasia alpha blockers market revenue, by type
- 10.1.1.2 U.S. benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
- 10.1.2 U.S. Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
- 10.1.1 U.S. Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 10.2 Market Revenue, by End User
Chapter 11. Canada Market Size and Forecast
- 11.1 Market Revenue, by Type
- 11.1.1 Canada Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 11.1.1.1 Canada benign prostatic hyperplasia alpha blockers market revenue, by type
- 11.1.1.2 Canada benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
- 11.1.2 Canada Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
- 11.1.1 Canada Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 11.2 Market Revenue, by End User
Chapter 12. Europe Market Size and Forecast
- 12.1 Overview
- 12.2 Market Revenue, by Type
- 12.2.1 Europe Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 12.2.1.1 Europe benign prostatic hyperplasia alpha blockers market revenue, by type
- 12.2.1.2 Europe benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
- 12.2.2 Europe Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
- 12.2.1 Europe Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 12.3 Market Revenue, by End User
- 12.4 Market Revenue, by Country
Chapter 13. Germany Market Size and Forecast
- 13.1 Market Revenue, by Type
- 13.1.1 Germany Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 13.1.1.1 Germany benign prostatic hyperplasia alpha blockers market revenue, by type
- 13.1.1.2 Germany benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
- 13.1.2 Germany Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
- 13.1.1 Germany Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 13.2 Market Revenue, by End User
Chapter 14. France Market Size and Forecast
- 14.1 Market Revenue, by Type
- 14.1.1 France Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 14.1.1.1 France benign prostatic hyperplasia alpha blockers market revenue, by type
- 14.1.1.2 France benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
- 14.1.2 France Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
- 14.1.1 France Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 14.2 Market Revenue, by End User
Chapter 15. U.K. Market Size and Forecast
- 15.1 Market Revenue, by Type
- 15.1.1 U.K. Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 15.1.1.1 U.K. benign prostatic hyperplasia alpha blockers market revenue, by type
- 15.1.1.2 U.K. benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
- 15.1.2 U.K. Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
- 15.1.1 U.K. Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 15.2 Market Revenue, by End User
Chapter 16. APAC Market Size and Forecast
- 16.1 Overview
- 16.2 Market Revenue, by Type
- 16.2.1 APAC Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 16.2.1.1 APAC benign prostatic hyperplasia alpha blockers market revenue, by type
- 16.2.1.2 APAC benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
- 16.2.2 APAC Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
- 16.2.1 APAC Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 16.3 Market Revenue, by End User
- 16.4 Market Revenue, by Country
Chapter 17. China Market Size and Forecast
- 17.1 Market Revenue, by Type
- 17.1.1 China Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 17.1.1.1 China benign prostatic hyperplasia alpha blockers market revenue, by type
- 17.1.1.2 China benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
- 17.1.2 China Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
- 17.1.1 China Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 17.2 Market Revenue, by End User
Chapter 18. Japan Market Size and Forecast
- 18.1 Market Revenue, by Type
- 18.1.1 Japan Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 18.1.1.1 Japan benign prostatic hyperplasia alpha blockers market revenue, by type
- 18.1.1.2 Japan benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
- 18.1.2 Japan Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
- 18.1.1 Japan Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 18.2 Market Revenue, by End User
Chapter 19. South Korea Market Size and Forecast
- 19.1 Market Revenue, by Type
- 19.1.1 South Korea Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 19.1.1.1 South Korea benign prostatic hyperplasia alpha blockers market revenue, by type
- 19.1.1.2 South Korea benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
- 19.1.2 South Korea Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
- 19.1.1 South Korea Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 19.2 Market Revenue, by End User
Chapter 20. India Market Size and Forecast
- 20.1 Market Revenue, by Type
- 20.1.1 India Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 20.1.1.1 India benign prostatic hyperplasia alpha blockers market revenue, by type
- 20.1.1.2 India benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
- 20.1.2 India Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
- 20.1.1 India Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 20.2 Market Revenue, by End User
Chapter 21. LATAM Market Size and Forecast
- 21.1 Overview
- 21.2 Market Revenue, by Type
- 21.2.1 LATAM Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 21.2.1.1 LATAM benign prostatic hyperplasia alpha blockers market revenue, by type
- 21.2.1.2 LATAM benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
- 21.2.2 LATAM Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
- 21.2.1 LATAM Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 21.3 Market Revenue, by End User
- 21.4 Market Revenue, by Country
Chapter 22. MEA Market Size and Forecast
- 22.1 Overview
- 22.2 Market Revenue, by Type
- 22.2.1 MEA Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 22.2.1.1 MEA benign prostatic hyperplasia alpha blockers market revenue, by type
- 22.2.1.2 MEA benign prostatic hyperplasia 5 alpha reductase inhibitors market revenue, by type
- 22.2.2 MEA Benign Prostatic Hyperplasia Surgical Treatment Market Revenue, by Type
- 22.2.1 MEA Benign Prostatic Hyperplasia Drugs Market Revenue, by Type
- 22.3 Market Revenue, by End User
- 22.4 Market Revenue, by Country
Chapter 23. Competitive Landscape
- 23.1 List of Market Players and Their Offerings
- 23.2 Market Share Analysis of Key Players
- 23.2.1 Global BPH Drugs Market
- 23.2.2 Global BPH Surgical Treatment Market
- 23.3 Competitive Analysis of Key Players
- 23.4 Product Comparison of Key Players
- 23.5 Recent Strategic Developments of Key Players
- 23.5.1 Partnerships & Acquisitions
- 23.5.2 Geographical Expansions
- 23.5.3 Product Launches
- 23.5.4 Other Developments
Chapter 24. Company Profiles
- 24.1 Astellas Pharma Inc.
- 24.1.1 Business Overview
- 24.1.2 Product and Service Offerings
- 24.1.3 Key Financial Summary
- 24.2 Alembic Pharmaceuticals Limited
- 24.2.1 Business Overview
- 24.2.2 Product and Service Offerings
- 24.2.3 Key Financial Summary
- 24.3 Unilab Inc.
- 24.3.1 Business Overview
- 24.3.2 Product and Service Offerings
- 24.4 Pharex Health Corporation
- 24.4.1 Business Overview
- 24.4.2 Product and Service Offerings
- 24.5 Biolitec AG
- 24.5.1 Business Overview
- 24.5.2 Product and Service Offering
- 24.6 Urologix LLC
- 24.6.1 Business Overview
- 24.6.2 Product and Service Offerings
- 24.7 Advin Health Care
- 24.7.1 Business Overview
- 24.7.2 Product and Service Offerings
- 24.8 Asclepion Laser Technologies GmbH
- 24.8.1 Business Overview
- 24.8.2 Product and Service Offerings
- 24.9 Pnn Medical A/S
- 24.9.1 Business Overview
- 24.9.2 Product and Service Offerings
- 24.10 Quanta Systems
- 24.10.1 Business Overview
- 24.10.2 Product and Service Offerings
- 24.11 Abbott Laboratories
- 24.11.1 Business Overview
- 24.11.2 Product and Service Offerings
- 24.11.3 Key Financial Summary
- 24.12 Asahi Kasei Corporation
- 24.12.1 Business Overview
- 24.12.2 Product and Service Offerings
- 24.12.3 Key Financial Summary
- 24.13 Richard Wolf GmbH
- 24.13.1 Business Overview
- 24.13.2 Product and Service Offerings
- 24.14 Boston Scientific Corporation
- 24.14.1 Business Overview
- 24.14.2 Product and Service Offerings
- 24.14.3 Key Financial Summary
- 24.15 KARL STORZ SE & Co. KG
- 24.15.1 Business Overview
- 24.15.2 Product and Service Offerings
- 24.16 Teleflex Incorporated
- 24.16.1 Business Overview
- 24.16.2 Product and Service Offerings
- 24.16.3 Key Financial Summary
- 24.17 Olympus Corporation
- 24.17.1 Business Overview
- 24.17.2 Product and Service Offerings
- 24.17.3 Key Financial Summary
- 24.18 Pfizer Inc.
- 24.18.1 Business Overview
- 24.18.2 Product and Service Offerings
- 24.18.3 Key Financial Summary
- 24.19 Merck & Co. Inc.
- 24.19.1 Business Overview
- 24.19.2 Product and Service Offerings
- 24.19.3 Key Financial Summary
- 24.20 Eli Lilly and Company
- 24.20.1 Business Overview
- 24.20.2 Product and Service Offerings
- 24.20.3 Key Financial Summary
- 24.21 GlaxoSmithKline plc
- 24.21.1 Business Overview
- 24.21.2 Product and Service Offerings
- 24.21.3 Key Financial Summary
- 24.22 Allergan plc
- 24.22.1 Business Overview
- 24.22.2 Product and Service Offerings
- 24.22.3 Key Financial Summary
- 24.23 IPG Photonics Corporation
- 24.23.1 Business Overview
- 24.23.2 Product and Service Offerings
- 24.23.3 Key Financial Summary
- 24.24 Sanofi
- 24.24.1 Business Overview
- 24.24.2 Product and Service Offerings
- 24.24.3 Key Financial Summary
- 24.25 Allium Medical Solutions Ltd.
- 24.25.1 Business Overview
- 24.25.2 Product and Service Offerings
- 24.26 SRS Medical
- 24.26.1 Business Overview
- 24.26.2 Product and Service Offerings
- 24.27 Convergent Laser Technologies
- 24.27.1 Business Overview
- 24.27.2 Product and Service Offerings
- 24.28 AbbVie Inc.
- 24.28.1 Business Overview
- 24.28.2 Product and Service Offerings
Chapter 25. Appendix
- 25.1 Sources and References
- 25.2 Related Reports
